NCT06907329View on ClinicalTrials.gov

The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.

NARecruitingINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

ImmunosenescenceMetabolism

Interventions

DIETARY_SUPPLEMENT

NMN

NMN SR tablets(1000mg/tablets) , 1 tablet daily before breakfast

DIETARY_SUPPLEMENT

Placebo

Matching Placebo (tablets) once daily before breakfast

Trial Locations (1)

Unknown

RECRUITING

Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors

lead

Qing Su

OTHER

NCT06907329 - The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders. | Biotech Hunter | Biotech Hunter